Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 41 of 41 results for golimumab

  1. NICE highlighted the importance of collecting further data within registries of patients receiving biological treatments for psoriatic arthritis to obtain information on long-term outcomes, including adverse events.

    None. Source guidance details Comes from guidance Golimumab for the treatment of psoriatic arthritis Number TA220 Date

    Research recommendation
    Published
    9 June 2015

  2. Vedolizumab for treating moderately to severely active ulcerative colitis (TA342)

    Evidence-based recommendations on vedolizumab (Entyvio) for treating moderate to severe ulcerative colitis in adults.

    Technology appraisal guidance
    Published
    5 June 2015
    View recommendations

    Sections for TA342

  3. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329)

    Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.

    Technology appraisal guidance
    Published
    25 February 2015
    View recommendations

    Sections for TA329

  4. Tocilizumab for the treatment of rheumatoid arthritis (TA247)

    Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    22 February 2012
    View recommendations

    Sections for TA247

  5. Golimumab for the treatment of ankylosing spondylitis (TA233)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

    Technology appraisal guidance
    Published
    24 August 2011

  6. Golimumab for the treatment of methotrexate-naive rheumatoid arthritis (terminated appraisal) (TA224)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Technology appraisal guidance
    Published
    22 June 2011

  7. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs (TA225)

    Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.

    Technology appraisal guidance
    Published
    22 June 2011
    View recommendations

    Sections for TA225

  8. Golimumab for the treatment of psoriatic arthritis (TA220)

    Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.

    Technology appraisal guidance
    Published
    27 April 2011
    View recommendations

    Sections for TA220

  9. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

    Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), rituximab (MabThera) and abatacept (Orencia). These drugs are for adults with severe rheumatoid arthritis who have tried other disease-modifying antirheumatic drugs (DMARDs) but cannot tolerate them or they haven’t worked well enough.

    Technology appraisal guidance
    Published
    25 August 2010
    View recommendations

    Sections for TA195

  10. Golimumab for treating moderately to severely active ulcerative colitis in people aged 2 to 17 years TS ID 11959

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Risankizumab for previously treated moderately to severely active ulcerative colitis in people aged 16 and over ID6209

    In development [GID-TA11184] Expected publication date: TBC

    Technology appraisal guidance
    In development